Loading
Outside US Medicare and Medicaid, joining a trial can leave the patient or hospital paying for the ordinary care that goes with it, and billing uncertainty blocks participation in middle-income countries. Requiring every insurer and public system to cover routine care costs removes a hidden barrier.
Legislation or payer policy guaranteeing coverage of routine patient care costs during trial participation, as US Medicare has since 2000 and Medicaid since the CLINICAL TREATMENT Act (effective 2022), extended to all private insurers, to national health systems that lack explicit rules, and to public insurers in middle-income countries where trial participation can be blocked by billing uncertainty.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).
Shares Trials enrol too few, too slowly, National Cancer Institute (NIH).